Does Ozempic contain semaglutide, and what does that mean for weight loss?

You have been reading about Ozempic for weight loss, here is where the confusion usually starts

Someone in your office lost two stone. They mentioned Ozempic. You searched online and found a sea of articles, social media posts and even sellers offering it without any medical involvement. It is an understandable starting point, because Ozempic really did spark widespread public interest in semaglutide as a weight-loss tool, largely driven by coverage from the United States, where its use grew rapidly before a dedicated weight-management product was widely available.

What those articles often glossed over is that Ozempic's UK licence covers glycaemic control in adults with type 2 diabetes, full stop. The NHS semaglutide medicines page is explicit on this. Prescribing it to someone who does not have type 2 diabetes, purely for weight loss, would be off-label, and no reputable UK weight-management clinic does it. The molecule works; the licensing is the issue.

Novo Nordisk's answer to the weight-loss demand was to develop a higher-dose semaglutide product specifically trialled and licensed for obesity. That product is Wegovy. The active ingredient is identical; the licensed indication, dose range and intended patient population are different. So the short answer to whether Ozempic contains semaglutide is yes, and the longer answer is that the brand name on the pen shapes what it can legally be prescribed for in this country.

What Ozempic's doses are, and why they differ from the weight-loss formulation

Ozempic is available in the UK in 0.5 mg, 1 mg and 2 mg weekly doses, stepped up gradually for diabetes management. Wegovy's schedule runs from 0.25 mg through to a 2.4 mg maintenance dose, with the MHRA having approved a 7.2 mg maintenance dose, initially as three 2.4 mg pens per week, then via a dedicated single-dose 7.2 mg pen approved on 14 April 2026. The dose ranges do not overlap in licensed use.

This also explains why trial results for Ozempic and Wegovy look different. The STEP 1 trial of semaglutide 2.4 mg for weight management, published in the New England Journal of Medicine, found roughly 15% average body-weight reduction over 68 weeks in adults with obesity. Ozempic studies at its diabetes doses show more modest weight effects, partly because the dose is lower and partly because the population and endpoints differ. Citing Ozempic data when a patient asks about weight-loss outcomes gives the wrong picture.

If you are curious about exactly what Wegovy contains beyond semaglutide itself (the excipients, the absorption mechanism) that detail is covered separately. The short version: both Ozempic and Wegovy are semaglutide injections, but only one is formulated and licensed at the doses studied for weight management in the UK.

What is actually licensed in the UK for weight management

Two injectable medicines hold UK licences for weight management in adults. Wegovy (semaglutide) is one. Mounjaro (tirzepatide) is the other, a dual GIP and GLP-1 receptor agonist made by Eli Lilly, and the only dual-agonist weight-loss medicine currently licensed in the UK. Both require a prescription following clinical assessment. Neither is Ozempic.

Wegovy is licensed for adults with a BMI of 30 or above, or 27 or above where at least one weight-related condition is present, high blood pressure, type 2 diabetes, high cholesterol, obstructive sleep apnoea and similar. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. NICE's appraisal of semaglutide for weight management (TA875) sets out the NHS recommendation in more detail, though NHS access involves specialist services and waiting lists for most people.

Private treatment through a GPhC-registered pharmacy is the other route. At nume, a GPhC-registered Independent Prescriber reads every consultation personally, not software, not a triage algorithm. If approved, treatment is dispatched the same day for orders placed before 12pm, arriving the next working day via DPD in plain, unbranded packaging. The pen itself is a pre-filled weekly injection; the discreet packaging means the box gives nothing away at the doorstep. You can also explore what Wegovy costs privately before committing to a consultation, which is always free.

Worth being clear: Rybelsus, also from Novo Nordisk, is yet another semaglutide formulation (this one an oral tablet) but it is licensed for type 2 diabetes at 3 mg, 7 mg and 14 mg doses. It is not the same as Wegovy tablets. The oral weight-loss tablet, approved by the MHRA on 11 June 2026, uses a different dosing schedule (1.5 mg up to 25 mg) and carries its own weight-management licence. Anybody who tells you Rybelsus is a weight-loss medicine for people without diabetes is working from the wrong information.

If Ozempic is not the answer, what should you do next

The starting point is an honest clinical conversation. Questions our prescribers hear regularly include whether a previous Ozempic prescription from abroad counts as a transfer, and whether someone who took Ozempic for diabetes can switch to Wegovy for weight management once their diabetes is controlled. Both are answerable, but only by a prescriber with your full picture.

There are also questions worth researching before that conversation. How semaglutide works across its different formulations is one. Whether Wegovy qualifies as a GLP-1 medicine is another that comes up when people are comparing treatment types. For anyone reading about a recent ophthalmology study involving semaglutide, the JAMA Ophthalmology research is discussed separately, including what it means practically. And if you have questions about whether semaglutide contains gluten (relevant for coeliac patients) the excipient detail is covered too.

If you are ready to find out whether Wegovy or Mounjaro might be clinically suitable for you, the free consultation at nume's treatment page is the place to start. No waiting list, no referral. A real prescriber reviews it the same day.